"The grand unifying goal in my research program is to understand the genetic and epigenetic bases of cancer progression and therapeutic responses in a systems manner. My lab will tackle the fundamental problems in cancer genetics and cancer immunology. We envision to innovate breakthrough technologies and discover fundamental biological insights that may ultimately be translated to more effective treatments for aggressive cancer types, especially primary brain tumors such as GBM."
- Dr. Sidi Chen
- Assistant Professor, Department of Genetics & Systems Biology Institute, Yale Cancer Center & Stem Cell Center, Yale University School of Medicine, 2015-present
About DSA-Funded Research
Glioblastoma (GBM) is a highly malignant primary brain tumor. Although GBM genomes were mapped in hundreds of patients, many new genes have never been functionally studied. Direct test of causality of various combinations of drivers and mechanistic characterization in the native brain tumor microenvironment are keys to deeper understanding of GBM. To generate new insights for enhancement of GBM therapeutics, we use interdisciplinary approaches, including basic molecular biology and genetics, functional genomics, systems biology, synthetic biology, genome engineering, in vivo animal modeling and high-throughput screening to find answers to fundamental problems in brain cancer biology. This project aims to provide a global quantitative picture the functional drivers in gliomagenesis and GBM tumor microenvironment, and to identify novel genetic interactions that might hint on pharmacological vulnerabilities. These advancements may provide insight on malignant transformation of glial cells in the brain, and potentially provide novel therapeutic targets for improved treatments for GBM patients.
"Sidi has demonstrated that he will be a highly successful scientist by executing on an innovative and exciting research program. Having witnessed the arrivals of many young colleagues at MIT, I can attest that even of those with equally strong postdoctoral records, only a fraction make this passage as impressively."
Philip A. Sharp, Ph.D.
Koch Institute for Integrative Cancer Research, MIT
"His laboratory is on track for fruitful scientific discoveries, with multiple manuscripts published and under review in high-quality journals. He has full academic independence, directs the research in his lab, and is already serving as senior authors in several manuscripts. I fully expect that his cutting edge research will transform the field and strongly impact human health."
Andre Levchenko, Ph.D.
Yale Systems Biology Institute